ZX-29, a novel ALK inhibitor, induces apoptosis via ER stress in ALK rearrangement NSCLC cells and overcomes cell resistance caused by an ALK mutation
- 1 July 2020
- journal article
- research article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1867 (7) , 118712
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
- National Natural Science Foundation of China
This publication has 28 references indexed in Scilit:
- Novartis' lung cancer ALK inhibitor approvedNature Biotechnology, 2014
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung CancerCancer Discovery, 2014
- Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on CrizotinibJournal of Thoracic Oncology, 2014
- A Modified Technique for Culturing Primary Fetal Rat Cortical NeuronsJournal of Biomedicine and Biotechnology, 2012
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung CancersScience Translational Medicine, 2012
- Ubiquitination and degradation of the FADD adaptor protein regulate death receptor-mediated apoptosis and necroptosisNature Communications, 2012
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisThe Lancet Oncology, 2011
- Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung CancerClinical Cancer Research, 2011
- Anaplastic Lymphoma Kinase (ALK)-Induced Malignancies: Novel Mechanisms of Cell Transformation and Potential Therapeutic ApproachesSeminars in Oncology, 2009
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007